{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.6","value":"4201.929"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"505.100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 12 to 24 hours post-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.4","value":"5787.139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"}],"units":"Participants"}],"title":"Cycle 1 Day 8 - End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"738.602"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"}],"units":"Participants"}],"title":"Cycle 1 Day 8 - 12 to 24 hours post-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.5","value":"13715.914"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"}],"units":"Participants"}],"title":"Cycle 1 Day 15 - End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.6","value":"1685.354"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"}],"units":"Participants"}],"title":"Cycle 1 Day 15 - 12 to 24 hours post-infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"}],"units":"Participants"}],"description":"Serum PK concentrations of tebentafusp were collected over time.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Tebentafusp administered at 20 mcg at Cycle 1 Day 1, 30 mcg at Cycle 1 Day 8, and 68 mcg at Cycle 1 Day 15 by IV infusion and weekly thereafter.","id":"OG000","title":"Tebentafusp"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK Analysis Set included participants in the Safety Analysis Set who had at least 1 measurable PK concentration and who had relevant date, time, and dosing data for the sample.","reportingStatus":"POSTED","timeFrame":"PK concentrations were assessed at pre-dose, end of infusion and anytime in the 12 to 24 hour window after completion of the infusion in Cycle 1 on Days 1, 8 and 15.","title":"Pharmacokinetics (PK): Tebentafusp Concentration","type":"SECONDARY","unitOfMeasure":"pg/mL"}